[1]
|
中华人民共和国国家卫生健康委员会医政医管局. 食管癌诊疗指南(2022年版) [J]. 中华消化外科杂志, 2022, 21(10): 1247-1268.
|
[2]
|
Kelly, R.J. (2019) Emerging Multimodality Approaches to Treat Localized Esophageal Cancer. Journal of the National Comprehensive Cancer Network, 17, 1009-1014. https://doi.org/10.6004/jnccn.2019.7337
|
[3]
|
Cheng, C., Zhuge, L., Xiao, X., et al. (2022) Overcoming Resistance to PD-1/PD-L1 Inhibitors in Esophageal Cancer. Frontiers in Oncology, 12, Article ID: 955163. https://doi.org/10.3389/fonc.2022.955163
|
[4]
|
Lyons, T.G. and Ku, G.Y. (2017) Systemic Therapy for Esoph-agogastric Cancer: Immune Checkpoint Inhibition. Chinese Clinical Oncology, 6, 53. https://doi.org/10.21037/cco.2017.09.03
|
[5]
|
Kitano, S. (2017) Anti-PD-1 Antibody and Anti-PD-Li Anti-body—From Basic and Clinic. Nihon Rinsho, 75, 201-207.
|
[6]
|
Kelly, R.J., Ajani, J.A., Kuzdzal, J., et al. (2021) Ad-juvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. The New England Journal of Medicine, 384, 1191-1203. https://doi.org/10.1056/NEJMoa2032125
|
[7]
|
何文武, 韩泳涛. 对CheckMate577: 纳武单抗在食管及食管胃结合部癌术后辅助治疗中的作用的述评[J]. 临床外科杂志, 2021, 29(8): 701-703.
|
[8]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
|
[9]
|
Kojima, T., Shah, M.A., Muro, K., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemo-therapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148.
https://doi.org/10.1200/JCO.20.01888
|
[10]
|
Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[11]
|
Harada, K., Yamamoto, S. and Kato, K. (2022) Pembroli-zumab: First Anti-PD-1/L1-Based Regimen for First-Line Treatment of Advanced Esophageal Cancer in Japan. Expert Opinion on Biological Therapy, 22, 1333-1338.
https://doi.org/10.1080/14712598.2022.2138327
|
[12]
|
Yang, W., Xing, X., Yeung, S.J., et al. (2022) Neoadjuvant Programmed Cell Death 1 Blockade Combined with Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. The Journal for ImmunoTherapy of Cancer, 10, e003497. https://doi.org/10.1136/jitc-2021-003497
|
[13]
|
季德林, 冯克海, 谢韬. 卡瑞利珠单抗 + 白蛋白紫杉醇 + 奈达铂/顺铂治疗老年晚期食管癌的临床疗效观察[J]. 中国现代医学杂志, 2022, 32(23): 6-10.
|
[14]
|
Yang, Y., Zhu, L., Cheng, Y., et al. (2022) Three-Arm Phase II Trial Comparing Camrelizumab plus Chemotherapy versus Camrelizumab plus Chemoradiation versus Chemoradiation as Preoperative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma (NICE-2 Study). BMC Cancer, 22, 506.
https://doi.org/10.1186/s12885-022-09573-6
|
[15]
|
Zheng, Y., Liu, X.B., Sun, H.B., et al. (2021) A Phase III Study on Neoadjuvant Chemotherapy versus Neoadjuvant Toripalimab plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Annals of Trans-lational Medicine, 9, 73.
https://doi.org/10.21037/atm-20-5404
|
[16]
|
He, W., Leng, X., Mao, T., et al. (2022) Toripalimab plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. Oncologist, 27, e18-e28.
https://doi.org/10.1093/oncolo/oyab011
|
[17]
|
Yu, R., Wang, W., Li, T., et al. (2021) RATIONALE 311: Tisleli-zumab plus Concurrent Chemoradiotherapy for Localized Esophageal Squamous Cell Carcinoma. Future Oncology, 17, 4081-4089. https://doi.org/10.2217/fon-2021-0632
|
[18]
|
Shen, L., Kato, K., Kim, S.B., et al. (2022) Tislelizumab versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. Journal of Clinical Oncology 40, 3065-3076. https://doi.org/10.1200/JCO.21.01926
|
[19]
|
Yan, X., Duan, H., Ni, Y., et al. (2022) Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Cancer: A Prospective, Single-Arm, Phase II Study (TD-NICE). International Journal of Surgery, 103, Article ID: 106680. https://doi.org/10.1016/j.ijsu.2022.106680
|
[20]
|
Park, S., Oh, D., Choi, Y.L., et al. (2022) Durvalumab and Tremelimumab with Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer, 128, 2148-2158. https://doi.org/10.1002/cncr.34176
|
[21]
|
van den Ende, T., de Clercq, N.C., van Berge He-negouwen, M.I., et al. (2021) Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-Arm Phase II Feasibility Trial (PERFECT). Clinical Cancer Research, 27, 3351-3359. https://doi.org/10.1158/1078-0432.CCR-20-4443
|
[22]
|
Bando, H., Kotani, D., Tsushima, T., et al. (2020) TENERGY: Multicenter Phase II Study of Atezolizumab Monotherapy Following Definitive Chemoradiotherapy with 5-FU plus Cisplatin in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma. BMC Can-cer, 20, 336. https://doi.org/10.1186/s12885-020-06716-5
|
[23]
|
Bang, Y.J., Ruiz, E.Y., Van Cutsem, E., et al. (2018) Phase III, Randomised Trial of Avelumab versus Physician’s Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300. Annals of Oncology, 29, 2052-2060.
https://doi.org/10.1093/annonc/mdy264
|
[24]
|
Zhang, Z., Ye, J., Li, H., et al. (2022) Neoadjuvant Sintilimab and Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Single-Arm, Phase 2 Trial. Frontiers in Immunology, 13, Article ID: 1031171. https://doi.org/10.3389/fimmu.2022.1031171
|
[25]
|
Lu, Z., Wang, J., Shu, Y., et al. (2022) Sintilimab versus Placebo in Combination with Chemotherapy as First Line Treatment for Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ORIENT-15): Multicentre, Randomised, Dou-ble Blind, Phase 3 Trial. BMJ, 377, e068714. https://doi.org/10.1136/bmj-2021-068714
|
[26]
|
Xu, J., Li, Y., Fan, Q., et al. (2022) Clinical and Biomarker Analyses of Sintilimab versus Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Randomized, Open-Label Phase 2 Study (ORIENT-2). Nature Communications, 13, 857. https://doi.org/10.1038/s41467-022-28408-3
|